Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
831 results about "Plasmid Vector" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
• Vector can be derived from a plasmid. • Vector is a plasmid or manipulated artificially after ligation and digestion reaction series, whereas a plasmid naturally occurs in bacterial cells. • There are several vectors, which can be used in recombinant DNA, whereas all plasmids may not be used directly in recombinant DNA technology.
Methods and cell line useful for production of recombinant adeno-associated viruses
InactiveUS7238526B2High yieldInduce expressionGenetically modified cellsGenetic material ingredientsPlasmid VectorAdeno associate virus
Methods for efficient production of recombinant AAV employ a host cell which comprising AAV rep and cap genes stably integrated within the cell's chromosomes, wherein the AAV rep and cap genes are each operatively linked to regulatory sequences capable of directing the expression of the rep and cap gene products upon infection of the cell with a helper virus, a helper gene, and a helper gene product. A method for producing recombinant adeno-associated virus (rAAV) involves infecting such a host cell with a helper virus, gene or gene product and infecting the infected host cell with a recombinant hybrid virus or plasmid vector containing adenovirus cis-elements necessary for replication and virion encapsidation, AAV sequences comprising the 5′ and 3′ ITRs of an AAV, and a selected gene operatively linked to regulatory sequences directing its expression, which is flanked by the above-mentioned AAV sequences.
Owner:THE TRUSTEES OF THE UNIV OF PENNSYLVANIA
Integration-free human induced pluripotent stem cells from blood
InactiveUS8048675B1Genetically modified cellsArtificial cell constructsPluripotential stem cellOrigin of replication
Provided herein are methods for generating human induced pluripotent stem cells free from genomic integration of exogenous transgenes by transfecting into nucleated blood cells one or more DNA expression vectors (e.g., plasmid vectors) that do not contain a mammalian origin of replication, and encode and permit expression of one or more reprogramming factors (e.g., Oct4, Sox2, Klf4, and c-Myc). Also provided herein are the integration-free human induced pluripotent stem cells obtained by the methods described herein.
Owner:TRUE NORTH THERAPEUTICS
Method of efficiently establishing induced pluripotent stem cells
ActiveUS20120196360A1Efficiently establishedImprove setup efficiencySugar derivativesGenetically modified cellsPlasmid VectorSomatic cell
Provided is a method of producing an iPS cell, comprising bringing (a) Oct3 / 4 or a nucleic acid that encodes the same, (b) Klf4 or a nucleic acid that encodes the same, and (c) Sox2 or a nucleic acid that encodes the same, as well as (d1) L-Myc or a nucleic acid that encodes the same and / or (d2) a functional inhibitor of p53, into contact with a somatic cell. It is preferable that (a) a nucleic acid that encodes Oct3 / 4, (b) a nucleic acid that encodes Klf4, (c) a nucleic acid that encodes Sox2, (d1) a nucleic acid that encodes L-Myc and (e) a nucleic acid that encodes Lin28 or Lin28b be inserted into an episomal vector having loxP sequences placed in the same orientation on the 5′ and 3′ sides of a vector constituent essential for the replication of the vector, that (d2) a nucleic acid that encodes an shRNA against p53 be inserted into a vector ensuring transient expression (plasmid vector and the like), and that all these nucleic acids be transferred to a somatic cell.
Owner:KYOTO UNIV
Intranasal delivery of nucleic acid molecules
InactiveUS20050265927A1Suppress gene expressionInhibit expressionPowder deliveryOrganic active ingredientsViral vectorExcipient
Aerosol delivery of nucleic acids to the lungs using viral vectors, polymers, surfactants, or excipients has been described. Compositions for intranasal administration are described that contain nucleic acids without viral or plasmid vectors and with little to no polymers, surfactants, or excipients. In one embodiment, the composition for intranasal delivery consists essentially of at least one nucleic acid and an aqueous solution. Suitable nucleic acids for intranasal delivery include, but are not limited to, dsDNA, dsRNA, ssDNA, ssRNA, short interfering RNA, micro-RNA, and antisense RNA. Methods for treatment, diagnosis, or prevention of at least one symptom or manifestation of a lung disease are also described consisting of administration by intranasal delivery an effective amount of a composition containing a nucleic acid. The composition may be formulated as a liquid or aerosol or other acceptable formulation for intranasal administration.
Owner:YALE UNIV
Recombinant DNA technology based information encrypting and hiding method and application
InactiveCN104734848AMeet safety requirementsIncrease the difficulty of crackingVector-based foreign material introductionSecuring communicationPlasmid VectorDNA fragmentation
The invention provides a recombinant DNA technology based information encrypting and hiding method and an application. Firstly, a plain text is coded into a DNA sequence, preprocessing is carried out on the DNA sequence by adopting the encryption algorithm, and a pseudo-DNA segment is generated; and then the pseudo-DNA segment and a marker gene segment are connected to a DNA plasmid vector by using the restriction enzyme and the ligase, and an obtained recombinant plasmid is further hided into a germ body; finally, a cell which contains confidential information is hided into a large number of irrelevant pseudo-cells, and the hided cells can be screened out by the selective cultivation. The encrypting and hiding method is applied to the authentication and signature technology. Encrypting, hiding and transmitting of the confidential information are achieved, and the cracking difficulty of a system is enhanced.
Owner:ZHENGZHOU UNIVERSITY OF LIGHT INDUSTRY
SSA (single-strand annealing) repair-based gene seamless editing method utilizing CRISPR/Cas9 technology
InactiveCN106011171ASeamless editingNucleic acid vectorVector-based foreign material introductionGenome editingPlasmid Vector
The invention mainly belongs to the technical field of gene editing and particularly relates to an SSA (single-strand annealing) repair-based gene seamless editing method utilizing a CRISPR / Cas9 technology. According to the gene seamless editing method, CRISPR / Cas9 expression vectors CCR5.CRISPR / Cas9 and eGFP.CRISPR / Cas9 targeting CCR5 and eGFP are constructed firstly, a donor CCR5-Donor vector is constructed, a CCR5-Donor plasmid vector adopts the pXL-BACII-L-arm-CAG-TK-PGK-Puro<R>-T2A-eGFP-bGH pA-R-arm structure, L-arm and R-arm are left and right homologous arms, and CAG-TK-PGK-Puro<R>-T2A-eGFP-bGH pA between L-arm and R-arm is a screening marking component; through two times of transfection, seamless editing is completed by using HR and SSA repair mechanisms in the CRISPR-Cas9 system and cells through positive and negative screening of puromycin and ganciclovir of the cells.
Owner:NORTHWEST A & F UNIV
MiR-205 gene knockout kit based on CRISPR-Cas9 gene knockout technology
ActiveCN105112445AVector-based foreign material introductionDNA/RNA fragmentationEnzyme digestionFluorescence
The invention discloses a miR-205 gene knockout kit based on CRISPR-Cas9 gene knockout technology. According to the invention, an optimal CRISPR-Cas9 target sequence of a certain amount of miR-205 is obtained through target design software and an sgRNA single chain is synthesized in vitro; an insertion fragment is obtained through processing; then sgRNA is inoculated into a plasmid vector by using T4 ligase; and a miR-205 gene knockout cell strain is obtained through transfection of an LNCap cell strain, continuous drug screening and fluorescence detection. Heterogenous hybridization double strands are obtained by extracting DNAs of a cell, PCR amplification of miR-205, purification, denaturation of a PCR product and annealing; T7E1 enzyme digestion test is employed to determining shearing efficiency of a CRISPR-Cas9 system on miR-205; a verified optimized a miR-205 gene knockout CRISPR-Cas9 target sequence is obtained; and the kit is constructed on the basis of the target sequence and can be used for directional knockout of miR-205 genes. The kit has the characteristics of high gene knockout efficiency, fast speed, easiness and economic performance and has wide prospects in the aspects of construction of animal models and clinical research of medical science.
Owner:广州辉园苑医药科技有限公司
Method of nuclear reprogramming
InactiveUS20100279404A1Easy to useElectric discharge tubesGenetically modified cellsPlasmid VectorNuclear reprogramming
This invention provides a method of producing an induced pluripotent stem cell comprising the step of introducing at least one kind of non-viral expression vector (more preferably a plasmid vector) incorporating at least one gene that encodes a reprogramming factor into a somatic cell. An induced pluripotent stem cell wherein no exogenous genes induced is integrated into the cellular genome is also provided.
Owner:KYOTO UNIV
Specific sgRNA combined with immunogene to inhibit HBV replication, expression vector thereof, and application of specific sgRNA and expression vector
ActiveCN105821039AImprove targetingHigh knockout efficiencyOrganic active ingredientsGenetic material ingredientsHepatitis B Virus AntigenIn vivo
The invention provides a specific sgRNA combined with an immunogene to inhibit HBV replication, an expression vector thereof, and an application of the specific sgRNA and the expression vector. The sgRNA sequences of a human hepatitis B virogene suitable for CRISPR-Cas9 targeting editing and a PD-1 gene are designed, the plasmid vector of the sgRNA inhibiting HBV and PD-1 genes is constructed, and the plasmid vector and a nuclease gene expression vector are transferred to HBV transgenic mice, and can obviously inhibit HBV DNA replication. The gene expression vector prepared in the invention has the advantages of simple method steps, good sgRNA targeting property, and high CRISPR-Cas9 knockout efficiency. The sgRNAs specifically targeting the HBV and PD-1 genes can accurately splice the HBV and PD-1 genes, inhibit in vivo hepatitis B virus replication, and reduce the hepatitis B virus antigen expression.
Owner:李旭
SgRNA combined with immunogene to inhibit high risk HPV expression, gene knockout vector thereof, and application of sgRNA and vector
ActiveCN105821040AImprove targetingGrowth inhibitionOrganic active ingredientsGenetic material ingredientsWilms' tumorCas9
The invention provides an sgRNA combined with immunogene to inhibit high risk HPV expression, a gene knockout vector thereof, and an application of the sgRNA and the vector. The sgRNA sequences of a human papilloma virus 16 type gene suitable for CRISPR-Cas9 targeting editing and a human PD-1 gene are selected, and the plasmid vector of the sgRNA and a CRISPR-Cas9 nuclease gene expression vector are transferred to HPV16+ human cervical carcinoma cells and HPV16+ transplantation tumor-bearing mice, and can obviously inhibit HPV16 expression and inhibit tumor growth. The gene expression vector prepared in the invention has the advantages of simple method steps, good sgRNA targeting property, high CRISPR-Cas9 knockout efficiency, accurate targeting splicing of high risk HPV16 type and PD-1 genes, efficient reduction of the expression of the high risk HPV16 type gene, and obvious inhibition of the tumor growth through combined application.
Owner:李旭
Genetically stable recombinant modified vaccinia ankara (RMVA) vaccines and methods of preparation thereof
ActiveUS20100316667A1Elicit immune responseVectorsSugar derivativesHeterologousModified vaccinia Ankara
A vaccine comprising an immunologically effective amount of recombinant modified vaccinia Ankara (rMVA) virus which is genetically stable after serial passage and produced by a) constructing a transfer plasmid vector comprising a modified H5 (mH5) promoter operably linked to a DNA sequence encoding a heterologous foreign protein antigen, wherein the expression of said DNA sequence is under the control of the mH5 promoter; b) generating rMVA virus by transfecting one or more plasmid vectors obtained from step a) into wild type MVA virus; c) identifying rMVA virus expressing one or more heterologous foreign protein antigens using one or more selection methods for serial passage; d) conducting serial passage; e) expanding an rMVA virus strain identified by step d); and f) purifying the rMVA viruses from step e) to form the vaccine. One embodiment is directed to a fusion cytomegalovirus (CMV) protein antigen comprising a nucleotide sequence encoding two or more antigenic portions of Immediate-Early Gene-1 or Immediate-Early Gene-2 (IEfusion), wherein the antigenic portions elicit an immune response when expressed by a vaccine.
Owner:CITY OF HOPE
Method for acquiring Nogo-B knockout mode mouse based on CRISPR/Cas9 technology and application thereof
The invention relates to a method for acquiring a Nogo-B knockout mode mouse based on CRISPR / Cas9 technology and an application thereof, the method for acquiring the Nogo-B knockout mode mouse comprises the following steps of: designing a high-efficiency sgRNA for identifying EGE-ZXH-007 of a specific gene; connecting the sgRNA to a plasmid vector and then carrying out in-vitro transcription to obtain a Ca9 / sgRNA capable of being subject to microinjection; injecting the Ca9 / sgRNA capable of being subject to microinjection into a mouse fertilized egg, and then carrying out genotype detection and identification on the born mouse, and finally obtaining the Nogo-B knock-out mode mouse. According to the invention, the Nogo-B knockout mode mouse is obtained by using the CRISPR / Case9 technology,and compared with the traditional gene knockout technology, the operation is easy and the efficiency is higher, and the homozygous mutation is more easily obtained, thus laying a good foundation for further researching the function of Nogo-B.
Owner:GENERAL HOSPITAL OF PLA
Method of producing induced pluripotent stem cells using inhibitors of P53
ActiveUS8900871B2Efficiently establishedImprove setup efficiencyBiocideNucleic acid vectorPlasmid VectorSomatic cell
Owner:KYOTO UNIV
Precision and high-efficiency transgenic carrier as well as construction method and application thereof
ActiveCN107760715AReduce workloadReduce subsequent crossesStable introduction of DNAVector-based foreign material introductionA-DNACatalytic effect
The invention discloses a precision and high-efficiency transgenic carrier as well as a construction method and application thereof. The transgenic carrier is obtained by completely assembling a genecoding CRISPR / Cas9 proteins, a DNA template of gRNAs, a homologous arm of a target gene side wing and a target gene to be transferred into a same plasmid vector. By adopting the precision and high-efficiency transgenic carrier as well as the construction method and application thereof, the workload and the subsequent hybridization for operating the gene in a laboratory can be significantly reduced, the homozygote generation time can be shortened, and the transgenic efficiency can be significantly increased. Based on an MCR method, the external target gene and the Cas9 gene are jointly transferred into silkworm genome in the process for precisely modifying the gene by virtue of the catalytic effect of the Cas9, the homozygote can be generated in a G0 generation, i.e. the mutation generatedon one copy can be automatically propagated onto an allele.
Owner:山东菌胜生物科技有限责任公司
Broad host range vectors for shotgun and expression library cloning in Gram negative bacteria
ActiveUS7846688B2Improve stabilityNucleotide librariesMicroorganism librariesExpression LibraryPlasmid Vector
The present invention concerns methods and compositions for the construction of a series of stable vectors for genomic library construction useful in Gram negative species. In certain embodiments, the vectors contain the pBBR1 replicon, capable of to stable replication in a broad range of Gram negative species. In various embodiments, the plasmid vectors may also contain bidirectional, rho-independent transcriptional terminators flanking the multiple cloning site, which allows for greater insert stability, and thus, greater genomic representation. Each vector may vary in its selection marker region, mobilization function, and promoter used to express insert sequences. These vectors are of use in the screening of highly representational genomic libraries in a broad variety of Gram negative species.
Owner:UNIV OF COLORADO THE REGENTS OF
LMNA gene knocked-out cell line constructed on basis of CRISPR/Cas9 technology
InactiveCN108410911APrecise and Efficient KnockoutGenetically modified cellsStable introduction of DNAPremature agingPremature senility syndrome
The invention discloses an LMNA gene knocked-out cell line. The cell line is a 293T cell line or a HePG2 tumor cell line. Cells to be knocked out are transfected by plasmid vectors constructed by twopairs of gRNA as shown in SEQ ID NO. 1-4 or two pairs of gRNA as shown in SEQ ID NO. 7-10 on the basis of a crispr-cas9 technology, and then are subjected to resistance screening to obtain the cell line. The LMNA gene knocked-out cell line can be used for intervention drug screening cell models for diseases such as dilated cardiomyopathy, fat metabolic disorder syndrome and premature aging syndromes.
Owner:GUANGXI MEDICAL UNIVERSITY
Stable knockout single plasmid vector with coordination of transposon and CRISPR/Cas9 system and application of stable knockout single plasmid vector
InactiveCN107686848ASimplify the build processThe process is simpleHydrolasesStable introduction of DNAStable cell lineBiology
The invention discloses a stable knockout single plasmid vector with coordination of transposon and a CRISPR / Cas9 system and application of stable knockout single plasmid vector and belongs to the field of gene engineering. The single plasmid vector is a double-stranded circular plasmid containing an IRDR-L-IRDR-R box, and the IRDR-L-IRDR-R box comprises an IRDR-L sequence, a promoter, a gRNA scaffold sequence, a Cas9 protein sequence, a resistance screening gene sequence and an IRDR-R sequence. The single plasmid vector provided by the invention can realize expression of sgRNA and a Cas9 protein only needing once construction and once transfection. A method is simple in process, is efficient and rapid, greatly simplifies a plasmid construction flow, shortens an experiment period and improves the working efficiency. The vector provided by the invention carries a transposase recognition sequence, does not use a virus, can conveniently, rapidly and safely establish a gene knockout stablecell line and is beneficial to screening stable cell lines by comprising the puromycin screening resistance.
Owner:SUN YAT SEN MEMORIAL HOSPITAL SUN YAT SEN UNIV
Recombinant expression plasmid vector stable in Hafnia alvei, and application thereof
The invention relates to a stable recombinant expression plasmid vector comprising a fragment of polynucleotide encoding a recombinant antitoxin gene. The polynucleotide expresses a polypeptide used for neutralizing toxic polypeptide of a host cell. The toxic polypeptide is expressed in a host cell by a fragment of polynucleotide encoding a toxin gene. The recombinant expression plasmid vector also comprises a fragment of polynucleotide encoding polypeptide expression product. The stable recombinant expression plasmid vector is derived by replicable frame plasmid in Hafnia alvei. The invention also discloses a transformant of the stable recombinant expression plasmid, a method for preparing bio-based pentanediamine by using the transformant, and bio-based pentanediamine prepared with the method provided by the invention. The invention also discloses polyamide and a composition containing polyamide, which are prepared by using the bio-based pentanediamine prepared with the method as a raw material. The invention also discloses a method for preparing pentamethylene-1,5-diisocyanate. The method comprises the steps that: bio-based pentanediamine is prepared by using the method provided by the invention; and the bio-based pentanediamine is transformed into pentamethylene-1,5-diisocyanate.
Owner:CATHAY R&D CENT CO LTD +1
Vaccines expressed in plants
The anti-viral vaccine of the present invention is produced in transgenic plants and then administered through standard vaccine introduction method or through the consumption of the edible portion of those plants. A DNA sequence encoding for the expression of a surface antigen of a viral pathogen is isolated and ligated to a promoter which can regulate the production of the surface antigen in a transgenic plant. This gene is then transferred to plant cells using a procedure that results in its integration into the plant genome, such as through the use of an Agrobacterium tumenfaciens plasmid vector system. Preferably, the foreign gene is expressed in an portion of the plant that is edible by humans or animals. In a preferred procedure, the vaccine is administered through the consumption of the edible plant as food, preferably in the form of a fruit or vegetable juice which can be taken orally.
Owner:PRODI GENE INC
Toxin/antitoxin systems and methods for regulating cellular growth, metabolic engineering and production of recombinant proteins
The present invention provides compositions and method for regulating cellular growth and metabolism, intra- and extracellular enzymatic activities, and synthesis of endogenous and / or heterologous proteins, comprising the steps of cloning genes encoding an mRNA interferase (toxin) and its cognate antitoxin; expressing these proteins in a host cell from two separate constitutive or inducible promoters on one or more plasmid vectors or on a chromosome; and regulating the cellular growth and metabolism by controlling the ratio of toxin and antitoxin present in the host cell. Optionally, the method provides further steps of modifying an endogenous or heterologous gene of interest to substitute all mRNA recognition sequences with sequences that are not cleavable by the mRNA interferase being expressed without any change in the amino acid sequence of the protein encoded by the gene; and co-expressing the gene of interest in the same host cell.
Owner:MAZEF BIOSCI
Construction method for sialidase gene knockout mouse model and application thereof
InactiveCN108486154AShort experiment cycleReduce experiment costVector-based foreign material introductionGlycosylasesCancer cellWilms' tumor
The invention relates to the field of biotechnologies, and provides a construction method for a sialidase gene knockout mouse model and application thereof. An in vitro and vivo targeted mouse genomeNPL is used for genetically recombining a CRISPR knockout plasmid vector, and a diploid double-knockout NPL mouse knockout model is successfully constructed through an oosperm microinjection technology. The NPL has the important function in a pathophysiological process of a body. Vicious transformation of a cancer cell is always along with overexpression of sialic acid. Now, the overexpression ofthe sialic acid has become one of important markers of the malignant transformation and transferring of a tumor. The model is capable of constructing a new research platform for researching a processof cell canceration, beneficial to a key step of researching generation and transferring of the tumor, and providing a foundation for the research and development of a novel anti-tumor drug.
Owner:FUZHOU UNIV
High-density fermentation and purification process for recombination high temperature-resistant hyperoxide dismutase
InactiveCN101275144AAvoid pollutionSimple purification processBacteriaMicroorganism based processesEscherichia coliDismutase
The present invention provides a high density fermentation and a purification process of a recombination high temperature resistance superoxide dismutase, the construction method of the invention includes: using gene coded for SOD in a thermophilic bacteria as a template, designing specific primer amplification target gene having restriction enzyme sites, after double digestion, connecting to plasmid vector pET28a after the same double digestion, constructing a recombinant plasmid, named for pSOD, transforming plasmid pSOD to competence escherichia coli BL21(DE3) by chemical transformation method, obtaining strain having high SOD yield after screening, completing the construction of SOD engineering bacteria; the fermentation process includes four steps of first order seed culture, secondary order feed culture, batch fermentation and induced expression, fermentation product SOD is finally obtained; the fermentation process realizes high level expression of SOD, the expression of the target protein is more than 60% of the bacterial protein total; SOD has excellent thermal stability and heat resistance, the expression product accounts for more than 60% of the whole proteins, and fully soluble protein, avoiding any trouble in the course of inclusion body renaturation; the purification process is simple, having high yield, lower cost, the final product SOD has high purification, high activity and strength stability.
Owner:YANGTZE DELTA REGION INST OF TSINGHUA UNIV ZHEJIANG +1
Tumor immunization method combining with chimeric antigen T cells targeting at PD-1 (programmed cell death protein 1) and EGFR (epidermal growth factor receptor)
InactiveCN107034235AIncrease lethalityImprove homingGenetically modified cellsMammal material medical ingredientsTumor targetEGFR Antibody
The invention discloses a tumor immunization method combining with chimeric antigen T cells targeting at PD-1 (programmed cell death protein 1) and EGFR (epidermal growth factor receptor) and also discloses a plasmid vector for implementing the method. In combination with fourth-generation CAR-T (chimeric antigen receptor T) cells targeting at PD-1 and EGFR, a lentiviral vector is used as a CAR-T vector basic structure, and truncated EGFR antibody is selected as a CAR core to give tumor targeted enrichment to play, tumor-killing effect is given to play in conformity with overexpressed immune checkpoint inhibitor PD-1 monoclonal antibody; by constructing the fourth-generation CAR-T vector for co-expressing various regulatory factors such as IL21, CCR4 and Bcl2, the killing, homing and persistent proliferating abilities of CAR-T cells are improved. EP-CAR T (esophageal papilloma chimeric antigen receptor T) cells are treated by transducing patient's autologous T-lymphocytes in vitro, amplifying suitably and transducing back to the patient's body via autologous transfusion, and no reports on similar designs of CAR-T cells are provided at present.
Owner:尹荣
Genetically stable recombinant modified vaccinia ankara (rMVA) vaccines and methods of preparation thereof
Owner:CITY OF HOPE
Strong promoter and plasmid vector containing strong promoter and application of strong promoter and plasmid vector
According to the invention, through amplifying a strong promoter in Ensifer adhaerens and carrying out bioinformatics analysis and functional verification, a strong promoter is obtained, and the strong promoter can be widely used for gene expression, genetic manipulation and strain improvement in Sinorhizobium meliloti, Zymomonas mobilis, Caulobacter crescentus, Pseudomonas denitrificans, Agrobacterium tumefaciens, Brucella abortus, Pseudomonas fluorescens, Rhizobium leguminosarum, Ensifer adhaerens and other alpha-proteobacteria and has a nucleotide sequence of SEQ ID NO: 1. The invention also relates to a plasmid vector containing the strong promoter, a method for constructing a genetic engineering strain by using the strong promoter, and an application of the corresponding strain and ahost cell in starting expression of a target gene.
Owner:TIANJIN INST OF IND BIOTECH CHINESE ACADEMY OF SCI
Recombinant adenovirus of porcine reproductive and respirator syndrome virus and porcine Circovirus, and vaccine
InactiveCN1800375AHas the copy featureStable potencyViruses/bacteriophagesAntibody medical ingredientsEscherichia coliCircovirus
The invention relates to a pig breeding and breathing complex virus (PPRSV) and pig 2-type loop virus (PCV 2) series gene recombination adenovirus and vaccine in the field of high and new biotechnology. It uses PCR technology to clone the Cap protein gene into the plasmid carrier pShuttle-CMV-GP5 by open type reading rule and transforms tobacillus coli BJ5183strain with cage carrier pAdEasy-1 to capture the recombination plasmid; it uses recombination plasmid HEK293-A cell to capture recombination adenovirus and purifies it to express the recombination adenovirus rAd-Cap-GP5 of PRRSV GP5protein and PCV-2 Cap protein.
Owner:NANJING AGRICULTURAL UNIVERSITY
Method for specific integration of t7 rna polymerase gene in the chromosome of corynebacterial and the resultant corynebacteria-t7 promoter based shuttle vector system
The present invention relates to method for obtaining optimum expressed proteins in a transformed gram positive bacteria by specific integration of T7 RNA polymerase gene into the chromosome of a gram positive bacteria exhibiting resistance to aminoglycosides, said method comprising:- digesting an E. coli plasmid with a restriction enzyme- digesting the genomic DNA of said gram positive bacteria- ligating the said digested plasmid to the digested genomic DNA of said gram positive bacteria- transforming the said gram positive bacteria protoplasts with the said ligation mixture of step 2 to yield transformed gram positive bacteria (transformants),- screening the said transformants for kanamycin resistance and aminoglycoside sensitivity to ensure that the targetting of the said plasmid vector into the chromosome of the said gram positive bacteria is successful- cloning of the desired gene in the said vector—culturing the transformant in a suitable culture medium- isolating the expressed proteins from the culture medium
Owner:INDIAN INST OF TECH
Methods and compositions for NAD(P)(H) oxidases
The present invention is directed to compositions and methods comprising NAD(P)H oxidases, particularly bacterial oxidases, nucleic acids, recombinant plasmid vectors and recombinant proteins therein encoded, and host cells comprising the oxidases and nucleic acids. The present invention also comprises an isolated bacterial oxidase that oxidizes both NADH and NADPH. Methods for producing the enzymes and enzymatic reactions comprising use of NAD(P)H oxidases and products of such reactions are also disclosed.
Owner:GEORGIA TECH RES CORP
Tobacco PDS gene fragment-containing cucumber mosaic virus RNA2 attenuated mutant type plasmid vector and application thereof
ActiveCN108486148AMeet basic requirementsSsRNA viruses positive-senseVirus peptidesNicotiana tabacumPlasmid Vector
The invention discloses a tobacco PDS gene fragment-containing cucumber mosaic virus RNA2 attenuated mutant type plasmid vector and application thereof. The plasmid vector contains a CMVFny strain RNA2 complete sequence, and a tobacco PDS gene 199bp fragment is inserted behind a 2a protein termination codon. The plasmid vector and a wild CMVFny RNA1 and wild CMVFny RNA3-containing plasmid are inoculated to nicotiana benthamiana through an agrobacterium infiltration method, so that weakly pathogenic symptoms can be displayed, and the capacity of inducing gene silencing can be judged with nakedeyes without depending on an instrument; great convenience is provided for deep researches on attenuated vaccines.
Owner:SHANDONG AGRICULTURAL UNIVERSITY
Gateway cloning entry vector, construction method and use thereof
The invention discloses a gateway cloning technology entry plasmid vector. The vector contains a photoinducible promoter (Prbcs) of a small subunit gene of 1,5-bisphosphate carboxylase (Rubisco) and a green fluorescent protein (GFP) reporter gene. The invention also discloses a construction method and application of the vector. Through the vector, the gateway cloning technology can be utilized to quickly construct a photoinducible plant expression vector of a target gene to realize the high level expression of the target gene in plant leaves, the expression of the target gene is adjusted by light intensity, and expressed target protein can be positioned into chloroplast or cytoplasm.
Owner:KUNMING UNIV OF SCI & TECH
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com